Results of GE Healthcare-supported economic modeling of a retrospective
meta-analysis of published literature were presented today at the SCAI
2014 Scientific Sessions in Las Vegas, NV. The model showed that
iso-osmolar contrast media was associated with lower overall cost –
nearly $700 savings per patient - when compared to low-osmolar contrast
media in regard to contrast-induced acute kidney injury (CI-AKI).1
“Contrast-induced acute kidney injury has major implications including
morbidity and health resource utilization,” said Swapnil Hiremath, MD,
Assistant Professor Medicine in the Division of Nephrology at the
University of Ottawa and lead author of the study. “This study provides
complementary and supportive CI-AKI data to the recently published
meta-analyses by McCullough and Dong comparing contrast-induced
nephrotoxicity of iso-osmolar and low-osmolar contrast media and
ascribes an economic value to those analyses.”2,3
About the Study
A systematic review and meta-analysis was conducted to estimate the risk
of acute kidney injury after use of iso- and low-osmolar contrast media.
A Markov model was then created, taking into account peri-procedural
risks, the differential risk of acute kidney injury, the need for
dialysis and subsequent mortality risk as well as cost associated with
the contrast media itself and treatment for downstream clinical events.
The model showed that use of iso-osmolar contrast resulted in a higher
quality adjusted life expectancy (29.19 versus 28.87 quality adjusted
life years), in addition to nearly $700 savings per patient. This result
was robust across most sensitivity analyses, including cost of contrast
media, baseline risk of acute kidney injury, volume of contrast used,
risk of dialysis. The exception was the sensitivity analysis with the
differential risk of acute kidney injury with iso-osmolar versus
low-osmolar contrast media.
“This study shows GE’s commitment to the continued advancement of
scientific knowledge of iodinated contrast media choice in the
interventional field, specifically highlighting health economics,” said
Jan Makela, General Manager, Core Imaging, GE Healthcare Life Sciences.
”We were particularly pleased to find the model reported cost savings
for iso-osmolar contrast even when taking into account upfront cost of
contrast.”
Safety Disclaimer
Serious, life-threatening and fatal reactions, mostly of cardiovascular
origin, have been associated with the administration of both iso-osmolar
and low osmolar iodine-containing contrast media. Most deaths occur
during injection or five to ten minutes later. Rare reports of
anaphylaxis have been documented during post-market surveillance. As
with other contrast agents, contrast media are often associated with
sensations of discomfort, warmth or pain. The reported incidence of
adverse reactions to contrast media in patients with a history of
allergy is twice that of the general population. Patients with a history
of a previous reaction to a contrast agent are three times more
susceptible than other patients.
About GE Healthcare
GE Healthcare provides transformational medical technologies and
services to meet the demand for increased access, enhanced quality and
more affordable healthcare around the world. GE (NYSE:GE) works on
things that matter - great people and technologies taking on tough
challenges. From medical imaging, software & IT, patient monitoring and
diagnostics to drug discovery, biopharmaceutical manufacturing
technologies and performance improvement solutions, GE Healthcare helps
medical professionals deliver great healthcare to their patients.
For our latest news, please visit http://newsroom.gehealthcare.com
1 Hiremath S, Akbari A, Wells G et al. Iso-osmolar Compared
to Low-osmolar Contrast Media for Contrast-induced Acute Kidney Injury:
A Cost-Effectiveness Analysis. Poster presented at the SCAI 2014
Scientific Sessions, Las Vegas, NV.
2 McCullough PA, Brown JR. Effects of Intra-Arterial and
Intravenous Iso-Osmolar Contrast Medium (Iodixanol) on the Risk of
Contrast-Induced Acute Kidney Injury: A Meta-Analysis Cardiorenal Med
2011;1:220–234
3 Dong M, Jiao Z, Liu T, et al. Effect of administration
route on the renal safety of contrast agents: a meta-analysis of
randomized controlled trials. J
Nephrol. 2012 May-Jun;25(3):290-301.
Copyright Business Wire 2014